Skip to main content
Top
Published in: Hormones 1/2024

20-11-2023 | Acromegaly | Original Article

Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly

Authors: Gokcen Unal Kocabas, Banu Sarer Yurekli, Ilgin Yildirim Simsir, Su Ozgur, Murat Aksit, Giray Bozkaya

Published in: Hormones | Issue 1/2024

Login to get access

Abstract

Purpose

The OPG/RANKL (osteoprotegerin/receptor activator of nuclear factor kappa-B) system, which plays a crucial role in bone metabolism, is also associated with vascular calcification. Acromegaly is characterized by excessive secretion of growth hormone and insulin-like growth factor, and studies have demonstrated an elevated risk of cardiovascular disease in individuals with acromegaly. In this study, our objective was to investigate the relationship between OPG/RANKL and various cardiovascular risk scoring systems.

Methods

We recruited 44 consecutive acromegaly patients and 41 healthy controls with a similar age and gender distribution for this study.

Results

While RANKL levels were significantly higher in the acromegaly group compared to the controls, OPG levels were not found to be significantly different between the two groups. Furthermore, within the acromegaly group, RANKL levels were significantly higher in patients with active acromegaly compared to those with controlled acromegaly.
Osteoprotegerin levels showed a positive correlation with the Framingham risk score (FRS) in the acromegaly group. Linear regression analysis revealed an association of OPG with FRS (adjusted R2 value of 21.7%).

Conclusion

OPG and RANKL may serve as potential markers for assessment of cardiovascular calcification and prediction of the cardiovascular risk status in acromegalic patients.
Literature
9.
go back to reference Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, Gulati M, Masoudi FA, Goff DC Jr (2017) Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 69:1617–1636. https://doi.org/10.1016/j.jacc.2016.10.018CrossRefPubMed Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, Gulati M, Masoudi FA, Goff DC Jr (2017) Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 69:1617–1636. https://​doi.​org/​10.​1016/​j.​jacc.​2016.​10.​018CrossRefPubMed
10.
go back to reference Ulloque-Badaracco JR, Hernandez-Bustamante EA, Alarcon-Braga EA, Mosquera-Rojas MD, Campos-Aspajo A, Salazar-Valdivia FE, Valdez-Cornejo VA, Benites-Zapata VA, Herrera-Anazco P, Valenzuela-Rodriguez G, Hernandez AV (2022) Atherogenic index of plasma and coronary artery disease: a systematic review. Open Med (Wars) 17:1915–1926. https://doi.org/10.1515/med-2022-0590CrossRefPubMed Ulloque-Badaracco JR, Hernandez-Bustamante EA, Alarcon-Braga EA, Mosquera-Rojas MD, Campos-Aspajo A, Salazar-Valdivia FE, Valdez-Cornejo VA, Benites-Zapata VA, Herrera-Anazco P, Valenzuela-Rodriguez G, Hernandez AV (2022) Atherogenic index of plasma and coronary artery disease: a systematic review. Open Med (Wars) 17:1915–1926. https://​doi.​org/​10.​1515/​med-2022-0590CrossRefPubMed
19.
go back to reference Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277. https://doi.org/10.1210/jc.2007-1213CrossRefPubMed Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277. https://​doi.​org/​10.​1210/​jc.​2007-1213CrossRefPubMed
21.
go back to reference Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, American College of Cardiology Foundation Clinical Expert Consensus Task F, Society of Atherosclerosis I, Prevention, Society of Cardiovascular Computed T (2007) ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 49:378–402. https://doi.org/10.1016/j.jacc.2006.10.001CrossRefPubMed Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, American College of Cardiology Foundation Clinical Expert Consensus Task F, Society of Atherosclerosis I, Prevention, Society of Cardiovascular Computed T (2007) ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 49:378–402. https://​doi.​org/​10.​1016/​j.​jacc.​2006.​10.​001CrossRefPubMed
25.
go back to reference Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM (2009) Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993–2003. Arterioscler Thromb Vasc Biol 29:975–980. https://doi.org/10.1161/ATVBAHA.109.184101CrossRefPubMed Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM (2009) Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993–2003. Arterioscler Thromb Vasc Biol 29:975–980. https://​doi.​org/​10.​1161/​ATVBAHA.​109.​184101CrossRefPubMed
Metadata
Title
Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly
Authors
Gokcen Unal Kocabas
Banu Sarer Yurekli
Ilgin Yildirim Simsir
Su Ozgur
Murat Aksit
Giray Bozkaya
Publication date
20-11-2023
Publisher
Springer International Publishing
Keyword
Acromegaly
Published in
Hormones / Issue 1/2024
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.1007/s42000-023-00509-8

Other articles of this Issue 1/2024

Hormones 1/2024 Go to the issue